Differences in Endothelial Function Amongst Sitagliptin and Liraglutide Users

PHASE4CompletedINTERVENTIONAL
Enrollment

13

Participants

Timeline

Start Date

March 31, 2013

Primary Completion Date

March 31, 2014

Study Completion Date

September 30, 2014

Conditions
DIABETES Mellitus Type 2 Not Well Controlled
Interventions
DRUG

Liraglutide

Liraglutide is available if pre-filled pens (6 mg/ml) as a solution for injection (Victoza®). One ml of solution contains 6 mg of Liraglutide (human glucagon-like peptide-1 analogue produced by recombinant DNA technology in Saccharomyces cerevisiae). One pre-filled pen contains 18 mg Liraglutide in 3 ml.

DRUG

Sitagliptin

Sitagliptin is available in 100 mg film-coated tablets (Januvia®). Each tablet contains sitagliptin phosphate monohydrate, equivalent to 100 mg sitagliptin.

Trial Locations (1)

08036

Hospital Clínic de Barcelona, Barcelona

All Listed Sponsors
lead

Anna Cruceta

OTHER

NCT01785043 - Differences in Endothelial Function Amongst Sitagliptin and Liraglutide Users | Biotech Hunter | Biotech Hunter